New drug cocktail aims to tackle tough lymphoma

NCT ID NCT06919939

Recruiting now Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study is testing whether combining two drugs—epcoritamab and loncastuximab tesirine—can safely shrink or eliminate lymphoma in people whose large B-cell lymphoma has come back or not responded to treatment. About 26 adults will receive the drugs over several cycles. The main goals are to check for side effects like cytokine release syndrome and liver problems, and to see how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Epcoritamab and Loncastuximab Tesirine
What this could lead to: If this combination works, it could offer a new treatment option for people with hard-to-treat large B-cell lymphoma that has come back or not responded to prior therapy.
What could go wrong: This is a small, early-phase trial (26 people) focused on safety and side effects, not yet proven to work. The drugs can cause serious side effects like cytokine release syndrome, nerve problems, and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARGE B-CELL LYMPHOMA RELAPSE

Contacts and locations

Locations

University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.